Tirzepatide for Obesity Treatment and Diabetes Prevention
New England Journal of Medicine · 26.06.2025 · 392 (24) · 2491-2493
DOI: 10.1056/nejmc2504728 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 26.06.2025. Verfasst von Andreas L Birkenfeld und 2 weiteren Autor:innen. Beteiligte Einrichtung: German Center for Diabetes Research Helmholtz Munich, Munich, Germany. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
To the Editor: Jastreboff and colleagues (March 6 issue) 1 investigated the preventive role of tirzepatide therapy with regard to the incidence of type 2 diabetes among trial participants with obesity, 41% of whom had prediabetes. Although the percentages of patients in the tirzepatide group who had remission of prediabetes to normal glucose values or in whom diabetes did not develop were impressive, the increase in the number of new cases of diabetes within 17 weeks in the off-treatment period, from 36 to 37 cases in the placebo group (increase, 3%) and from 10 to 18 cases in the tirzepatide group . . .
Autor:innen und Institutionen
- German Center for Diabetes Research Helmholtz Munich, Munich, Germany.
- New York University Grossman School of Medicine, New York.
- University Hospital Tübingen, Tübingen, Germany.
Zitieren
APA
Birkenfeld, A. L., Bergman, M., & Stefan, N. (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine, 392(24), 2491-2493. https://doi.org/10.1056/nejmc2504728
Vancouver
Birkenfeld AL, Bergman M, Stefan N. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2025;392(24):2491-2493. doi:10.1056/nejmc2504728
BibTeX
@article{Birkenfeld2025,
author = {Birkenfeld, Andreas L and Bergman, Michael and Stefan, Norbert},
title = {Tirzepatide for Obesity Treatment and Diabetes Prevention},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {24},
pages = {2491--2493},
doi = {10.1056/nejmc2504728}
}
EUVIMED